Adenosine 2A receptor agonism: A single intrathecal administration attenuates motor paralysis in experimental autoimmune encephalopathy in rats

Brain, Behavior, and Immunity

Volumn 46, Issue , 2015, Pages 50-54

  Loram, Lisa C ^a   Strand, Keith A ^a   Taylor, Frederick R ^a   Sloane, Evan ^a   Van Dam, Anne Marie ^b   Rieger, Jayson ^c   Maier, Steven F ^a   Watkins, Linda R ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Forest Labs Inc ^*  (United States)

Author keywords

ATL313; CGS21680; Multiple sclerosis; Myelin oligodendrocyte glycoprotein

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); BIOLOGICAL MARKER; CD163 ANTIGEN; CD68 ANTIGEN; EVODENOSON; PROTEIN OX 42; UNCLASSIFIED DRUG; 2-(4-(2-CARBOXYETHYL)PHENETHYLAMINO)-5'-N-ETHYLCARBOXAMIDOADENOSINE; ADENOSINE; ADENOSINE A2 RECEPTOR AGONIST; PHENETHYLAMINE DERIVATIVE; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY MASS; CELL ACTIVATION; CONTROLLED STUDY; DISEASE COURSE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUMBAR SPINAL CORD; MALE; MICROGLIA; MOTOR DYSFUNCTION; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SPINAL CORD DORSAL HORN; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; PARALYSIS; SPINAL CORD;

ADENOSINE; ADENOSINE A2 RECEPTOR AGONISTS; ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; MALE; MICROGLIA; PARALYSIS; PHENETHYLAMINES; PIPERIDINES; RATS; SPINAL CORD;

EID: 84928823303     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2015.01.014     Document Type: Article

References (24)

1. Ajami B., Bennett J.L., Krieger C., McNagny K.M., Rossi F.M. Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat. Neurosci. 2011, 14:1142-1149.
2. Buechler C., Eisinger K., Krautbauer S. Diagnostic and prognostic potential of the macrophage specific receptor CD163 in inflammatory diseases. Inflamm. Allergy Drug Targets 2013, 12:391-402.
3. Chen G.Q., Chen Y.Y., Wang X.S., Wu S.Z., Yang H.M., Xu H.Q., He J.C., Wang X.T., Chen J.F., Zheng R.Y. Chronic caffeine treatment attenuates experimental autoimmune encephalomyelitis induced by guinea pig spinal cord homogenates in Wistar rats. Brain Res. 2010, 1309:116-125.
4. Cohen H.B., Briggs K.T., Marino J.P., Ravid K., Robson S.C., Mosser D.M. TLR stimulation initiates a CD39-based autoregulatory mechanism that limits macrophage inflammatory responses. Blood 2013, 122:1935-1945.
5. Dai S.S., Zhou Y.G. Adenosine 2A receptor: a crucial neuromodulator with bidirectional effect in neuroinflammation and brain injury. Rev. Neurosci. 2011, 22:231-239.
6. Dare E., Schulte G., Karovic O., Hammarberg C., Fredholm B.B. Modulation of glial cell functions by adenosine receptors. Physiol. Behav. 2007, 92:15-20.
7. Deaglio S., Dwyer K.M., Gao W., Friedman D., Usheva A., Erat A., Chen J.F., Enjyoji K., Linden J., Oukka M., Kuchroo V.K., Strom T.B., Robson S.C. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 2007, 204:1257-1265.
8. Ferrante C.J., Pinhal-Enfield G., Elson G., Cronstein B.N., Hasko G., Outram S., Leibovich S.J. The adenosine-dependent angiogenic switch of macrophages to an M2-like phenotype is independent of interleukin-4 receptor alpha (IL-4Ralpha) signaling. Inflammation 2013, 36:921-931.
9. Hasko G., Cronstein B.N. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 2004, 25:33-39.
10. Hasko G., Pacher P., Deitch E.A., Vizi E.S. Shaping of monocyte and macrophage function by adenosine receptors. Pharmacol. Ther. 2007, 113:264-275.
11. Johnston J.B., Silva C., Gonzalez G., Holden J., Warren K.G., Metz L.M., Power C. Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis. Ann. Neurol. 2001, 49:650-658.
12. Ledeboer A., Wierinckx A., Bol J.G., Floris S., Renardel de Lavalette C., De Vries H.E., van den Berg T.K., Dijkstra C.D., Tilders F.J., van dam A.M. Regional and temporal expression patterns of interleukin-10, interleukin-10 receptor and adhesion molecules in the rat spinal cord during chronic relapsing EAE. J. Neuroimmunol. 2003, 136:94-103.
13. Loram L.C., Harrison J.A., Sloane E.M., Hutchinson M.R., Sholar P., Taylor F.R., Berkelhammer D., Coats B.D., Poole S., Milligan E.D., Maier S.F., Rieger J., Watkins L.R. Enduring reversal of neuropathic pain by a single intrathecal injection of adenosine 2A receptor agonists: a novel therapy for neuropathic pain. J. Neurosci. 2009, 29:14015-14025.
14. Loram L.C., Taylor F.R., Strand K.A., Harrison J.A., Rzasalynn R., Sholar P., Rieger J., Maier S.F., Watkins L.R. Intrathecal injection of adenosine 2A receptor agonists reversed neuropathic allodynia through protein kinase (PK)A/PKC signaling. Brain Behav. Immun. 2013, 33:112-122.
15. Mills J.H., Thompson L.F., Mueller C., Waickman A.T., Jalkanen S., Niemela J., Airas L., Bynoe M.S. CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:9325-9330.
16. Mills J.H., Kim D.G., Krenz A., Chen J.F., Bynoe M.S. A2A adenosine receptor signaling in lymphocytes and the central nervous system regulates inflammation during experimental autoimmune encephalomyelitis. J. Immunol. 2012, 188:5713-5722.
17. Moore C.C., Martin E.N., Lee G.H., Obrig T., Linden J., Scheld W.M. An A2A adenosine receptor agonist, ATL313, reduces inflammation and improves survival in murine sepsis models. BMC Infect. Dis. 2008, 8:141.
18. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008, 8:958-969.
19. Sloane E., Ledeboer A., Seibert W., Coats B., van Strien M., Maier S.F., Johnson K.W., Chavez R., Watkins L.R., Leinwand L., Milligan E.D., Van Dam A.M. Anti-inflammatory cytokine gene therapy decreases sensory and motor dysfunction in experimental multiple sclerosis: MOG-EAE behavioral and anatomical symptom treatment with cytokine gene therapy. Brain Behav. Immun. 2009, 23:92-100.
20. Tsutsui S., Schnermann J., Noorbakhsh F., Henry S., Yong V.W., Winston B.W., Warren K., Power C. A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J. Neurosci. 2004, 24:1521-1529.
21. Wang T., Xi N.N., Chen Y., Shang X.F., Hu Q., Chen J.F., Zheng R.Y. Chronic caffeine treatment protects against experimental autoimmune encephalomyelitis in mice: therapeutic window and receptor subtype mechanism. Neuropharmacology 2014, 86C:203-211.
22. Wei W., Du C., Lv J., Zhao G., Li Z., Wu Z., Hasko G., Xie X. Blocking A2B adenosine receptor alleviates pathogenesis of experimental autoimmune encephalomyelitis via inhibition of IL-6 production and Th17 differentiation. J. Immunol. 2013, 190:138-146.
23. Yao S.Q., Li Z.Z., Huang Q.Y., Li F., Wang Z.W., Augusto E., He J.C., Wang X.T., Chen J.F., Zheng R.Y. Genetic inactivation of the adenosine A(2A) receptor exacerbates brain damage in mice with experimental autoimmune encephalomyelitis. J. Neurochem. 2012, 123:100-112.
24. Zarek P.E., Huang C.T., Lutz E.R., Kowalski J., Horton M.R., Linden J., Drake C.G., Powell J.D. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 2008, 111:251-259.